What factors drove the changes in Longeveron's revenue and profit?

What guidance did Longeveron's management provide for the next earnings period?

What were the key takeaways from Longeveron’s earnings call?

What is Longeveron's latest dividend and current dividend yield?

What is the market's earnings forecast for Longeveron next quarter?

What is the revenue and EPS growth rate for Longeveron year over year?

Did Longeveron beat or miss consensus estimates last quarter?

What does Longeveron do and what are its main business segments?

- **$15M Capital Injection**: Secured by top investors, providing runway to Q4 2026 and enabling HLHS BLA preparation.
- **HLHS Pivotal Trial**: ELPIS-II results Q3 2026 could trigger rolling BLA submission, with PRV sale potential (~$100M+).
- **PDCM Strategic Priority**: IND-approved trial targeting 70 patients in 2027, aiming to reduce heart transplant rates in children.
- **Financial Challenges**: 50% revenue decline and $22.7M net loss, offset by $15.9M private placement extending liquidity.
- **Partnership Focus**: Alzheimer’s and frailty programs attract pharma interest, with CEO leveraging industry connections.

**【CEO Summary Section】**
- Secured $15 million in new capital from Coastlands Capital and Janus Henderson Investors, with potential for an additional $15 million upon milestones.
- HLHS phase 2b trial (ELPIS-II) enrollment completed in June 2025, with top-line results expected in Q3 2026. If successful, plans to prepare for BLA submission.
- Potential for Priority Review Vouchers (PRVs) in HLHS and PDCM programs, with 50% of HLHS PRV proceeds allocated to investors.
- Strategic focus on partnerships for Alzheimer’s disease and age-related frailty programs, leveraging CEO’s Rolodex of 24 global pharma companies.

**【CMO Clinical Update】**
- HLHS program: ELPIS-II trial designed to evaluate laromestrocel’s ability to improve right ventricular function and long-term outcomes in infants. FDA feedback indicates potential for rolling BLA submission if data supports efficacy.
- PDCM program: IND approved in July 2025, with plans for a single pivotal phase 2 trial targeting 70 patients, focusing on reducing heart transplant rates and hospitalizations.
- Female sexual dysfunction program: New patent granted, with potential for partnership due to high unmet need in post-menopausal women.

**【CFO Financial Commentary】**
- 2025 revenue: $1.2 million (down 50% YoY) due to reduced demand for contract manufacturing and clinical trials.
- Net loss: $22.7 million (up 41% YoY) driven by increased R&D ($12 million vs. $8.1 million) and G&A expenses ($12 million vs. $10.3 million).
- Cash position: $4.7 million as of Dec 31, 2025, with private placement proceeds extending runway into Q4 2026.

**【CSO Strategic Vision】**
- Stem cell therapy validation across regenerative medicine, with Longeveron’s laromestrocel showing potential in HLHS, PDCM, and age-related frailty.
- Focus on CMC advancements with a CDMO partner to enable commercial readiness for BLA submission.
- Alzheimer’s disease program: Incoming interest for licensing, leveraging phase 2 data and Cell Stem Cell publication.

**【Q&A Highlights】**
- **PRV Monetization**: CEO expects PRV prices to remain strong (~$200 million) despite 2029 sunset date, citing recent Fortis sale at $205 million.
- **Manufacturing Strategy**: Transitioning to CDMO for commercial production, freeing internal resources for pipeline expansion.
- **PDCM Trial Design**: Hierarchical composite endpoint (heart transplant/hospitalization reduction), global recruitment targeting 70 patients in 2027.
- **Frailty Licensing**: CEO actively engaging pharma partners, with interest driven by Cell Stem Cell publication on age-related frailty reversal.


Longeveron LLC (LGVN) Q4 2025 Earnings Call Transcript

- **HLHS Pivotal Trial Progress**: ELPIS II enrollment complete; results expected Q3 2026, with BLA submission now targeted for 2027. 
- **Financial Challenges**: 53% revenue decline in 2025 due to reduced clinical trial demand; net loss of $17.3 million. 
- **Manufacturing Readiness**: Third-party CMO partnership established; Miami facility generates incremental revenue. 
- **Strategic Focus**: Self-commercialization for HLHS; exploring partnerships for Alzheimer's and rare pediatric indications. 
- **Regulatory Updates**: Evaluating FDA expediting programs; long-term survival data key to reimbursement.

**【CEO Summary Section】**
- Than Powell emphasized the company's focus on advancing the Phase IIb ELPIS II trial for HLHS, with enrollment completed in June 2025 and results expected in Q3 2026. 
- The company has extended its cash runway into late Q1 2026 through cost optimization and an at-the-market (ATM) equity financing facility of up to $10.7 million. 
- BLA submission for HLHS is now anticipated in 2027, delayed from late 2026 due to CMC and manufacturing readiness timelines. 
- Strategic discussions are ongoing for potential partnerships in rare pediatric diseases, with a focus on leveraging laromestrocel's mechanism of action in neuroinflammation.

**【CFO Financial Commentary】**
- Revenues for the first 9 months of 2025 decreased by 53% to $0.8 million, driven by lower demand in the Bahamas Registry Trial and contract manufacturing services. 
- Clinical trial revenue declined 36% to $0.7 million, while contract manufacturing revenue fell 76% to $0.2 million. 
- Research and development expenses increased 52% to $9.3 million, reflecting investments in CMC activities and BLA-enabling studies. 
- The company reported a net loss of $17.3 million for the period, with cash reserves of $9.2 million as of September 30, 2025. 
- The ATM facility and potential grants or collaborations are key to securing future funding.

**【CTO & CMC Update】**
- Devin Blass announced a strategic partnership with a third-party CMO for commercial manufacturing, with proof-of-concept runs completed and master services agreement in final stages. 
- Technology transfer and process validation are progressing to support BLA readiness post-ELPIS II results. 
- The Miami cGMP facility continues to generate revenue through selective contract manufacturing, offsetting clinical development costs.

**【Q&A Highlights】**
- **Partnership Strategy**: Management prioritizes self-commercialization for HLHS due to the niche market and existing surgeon network, but remains open to partnerships for non-core indications. 
- **Lewy Body Dementia**: While not currently in development, the company acknowledges neuroinflammation as a potential mechanism for laromestrocel and may explore this indication post-Alzheimer's trials. 
- **Regulatory Pathway**: The company is evaluating rolling BLA submissions and the FDA's new Commissioner's National Priority Voucher program to expedite approval. 
- **Payer Engagement**: Long-term follow-up data from ELPIS I (5-year transplant-free survival) will be critical for reimbursement discussions.

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

- **HLHS Milestone**: Completed enrollment for pivotal Phase 2b trial, targeting BLA submission in late 2026 if data positive.
- **Pipeline Expansion**: Secured IND for pediatric DCM, with pivotal Phase 2 trial planned for H1 2026.
- **Financial Challenges**: H1 2025 net loss widened to $10M due to higher R&D and G&A expenses, though $5M raised in August 2025 public offering.
- **Strategic Manufacturing**: Partnering with CDMO to accelerate commercial readiness and reduce capital risk.
- **Innovative Technology**: Licensed iPSC-derived cardiomyogenic cells to avoid arrhythmia risks, positioning for safer heart failure treatments.

**【CEO Summary Section】**
- Completed enrollment for pivotal ELPIS II Phase 2b study in HLHS, targeting 40 patients with 2 over-enrolled due to high demand. Top-line results expected Q3 2026.
- Secured rare pediatric disease designation for HLHS, enabling rolling BLA submission if data supports approval in late 2026.
- Expanded pipeline with pediatric dilated cardiomyopathy (DCM) IND approval, targeting a pivotal Phase 2 trial in H1 2026.
- Licensed novel iPSC-derived cardiomyogenic cells technology to address arrhythmia risks in heart treatments.

**【CFO Financial Commentary】**
- Revenues for H1 2025: $0.7M (down 31% YoY) due to lower Bahamas registry trial demand and contract manufacturing services.
- Net loss widened to $10M (H1 2025) from $7.5M (H1 2024) due to increased R&D ($5.5M vs $3.9M) and G&A ($5.5M vs $4.3M) expenses.
- Cash balance $10.3M as of Q2 2025, with $5M raised in August 2025 public offering and potential $12.5M from warrant exercises.
- Anticipate cash runway into Q1 2026, with focus on securing nondilutive funding for Alzheimer's program and CMC readiness.

**【Q&A Key Highlights】**
- **Market Dynamics**: HLHS and DCM both orphan diseases with ~1,000-1,500 new cases annually. DCM has higher prevalence (2,000-3,000 patients) due to longer survival. Pricing strategies expected to be comparable but adjusted for administration method (one-time vs chronic infusion).
- **Regulatory Pathway**: FDA agreed Phase 2 DCM trial can be pivotal if endpoints met, leveraging HLHS trial success for supportive evidence. FDA interactions remain collaborative under new administration.
- **Manufacturing Strategy**: Partnering with CDMO for commercial manufacturing to accelerate BLA readiness, reduce capital expenditure, and mitigate regulatory risks.
- **iPSC Technology**: Differentiated by selection of non-arrhythmic cardiomyogenic cells, addressing key safety concern in heart failure treatments. Preclinical studies to begin soon.

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

- **HLHS Milestone Progress**: 95% enrollment in pivotal ELPIS II trial, BLA submission on track for 2026.
- **Alzheimer's Regulatory Clarity**: FDA-approved adaptive Phase II/III trial design, partnership hunt underway.
- **Financial Challenges**: Q1 revenue down 30%, net loss up 25%, seeking additional funding for BLA readiness.
- **Commercial Potential**: HLHS market valued at $0.5B+ annually, 65% penetration target.
- **Manufacturing Strategy**: 1,500-dose capacity in-house; CDMO partnerships for scalability.


**【CEO Opening Remarks】**
- HLHS Phase IIb trial (ELPIS II) nearing completion with 95% enrollment, targeting BLA submission in 2026.
- Alzheimer's disease program secured FDA alignment for a single pivotal Phase II/III trial, seeking partnerships for funding.
- Focus on commercial readiness for HLHS, with CDMO manufacturing options under evaluation.

**【CFO Financial Update】**
- Q1 2025 revenue $0.4M (down 30% YoY) due to declining Bahamas Registry Trial participation.
- Net loss $5.0M (up 25% YoY) driven by R&D and G&A expenses.
- Cash balance $14.3M, expected to last into Q3 2025; additional funding sought for BLA activities.

**【Clinical Development Highlights】**
- HLHS: 100% transplant-free survival in Phase I, ELPIS II results to support BLA.
- Alzheimer's: Phase IIa data published in *Nature Medicine*, FDA agreed to accelerated approval pathway.

**【Q&A Key Takeaways】**
- HLHS market potential: ~$0.5B+ annually in the U.S., 65% penetration assumption.
- FDA CBER leadership changes not impacting BLA preparation; regulatory alignment maintained.
- Manufacturing strategy: in-house capacity for 1,500 doses; CDMO partnership for scale.
- PRV eligibility: contingent on congressional reauthorization, strong bipartisan support anticipated.


Longeveron (LGVN)-8 May 25-2025 Q1 Earnings call transcript

- **HLHS Trial Momentum**: 90% enrollment in pivotal ELPIS II trial, with FDA greenlight for 2026 BLA submission.
- **Alzheimer's Breakthrough**: RMAT designation for Lomecel-B, with Phase IIa data showing disease stabilization.
- **Financial Strength**: 237% revenue growth to $2.4M, 25% net loss reduction, and $19.2M cash runway to Q4 2025.
- **Strategic Focus**: Accelerated path to approval for Alzheimer's, minimal commercial infrastructure for HLHS, and CMC readiness investments.

**【Management Opening Remarks】**
- Derek Cole provided an overview of the call, highlighting the press release availability and the company's leadership team.

**【CEO Summary Section】**
- **HLHS Program Progress**: Phase IIb ELPIS II trial is 90% enrolled, with FDA confirmation as pivotal for BLA submission in 2026. HLHS market opportunity estimated at $1 billion.
- **Alzheimer's Breakthrough**: Lomecel-B received RMAT and Fast Track designations, with Phase IIa data showing disease worsening prevention. FDA meeting scheduled for March to discuss accelerated path.
- **INN Name Approval**: Laromestrocel received WHO international non-proprietary name, advancing commercial readiness.

**【CMO Clinical Update】**
- **HLHS Enrollment Challenges**: Surgery timing delays caused enrollment delays, but 35/38 patients enrolled. FDA open to composite endpoints (e.g., RVEF, hospitalization) for 12-month follow-up.
- **Alzheimer's Regulatory Momentum**: RMAT designation positions Lomecel-B for accelerated approval. Global partnership discussions underway post-BLA submission.

**【CFO Financial Commentary】**
- **Revenue Growth**: 2024 revenue $2.4M (+237%), driven by contract manufacturing ($1M) and registry trial demand.
- **Cost Efficiency**: Operating expenses down 13% to $18.4M, with R&D (-10%) and G&A (-16%) reductions. Net loss reduced 25% to $16M.
- **Cash Position**: $19.2M as of Q4, sufficient for operations into Q4 2025. BLA readiness activities expected to accelerate 2025 spend, requiring additional funding.

**【Q&A Highlights】**
- **ELPIS II Enrollment**: Final 3-5 patients expected by Q2 2025, with no new sites needed. Top-line results anticipated summer 2026.
- **Commercial Strategy**: Minimal infrastructure (2-3 sales reps) for HLHS due to 50 U.S. surgeons. Alzheimer's focus on partnerships post-BLA.
- **Manufacturing Outlook**: Steady contract revenue ($1M in 2024), with CMC readiness prioritized for BLA submission.
- **Regulatory Strategy**: Seeking PRV extension for HLHS. No international Alzheimer's interactions yet; U.S. focus first.


Actual				-2.5	-2	-1.7	-2.7	-2.5	-2.1	-2.2	-2.7	-2.8	-2.5	-1.61	-1.83	-0.34	-0.4338	-0.34	-0.33	-0.39	-0.23
Forecast					-2.5	-2.25	-2.2667	-2.2	-2	-2.1333	-2.4667	-2.25	-2.1333	-2.005	-0.87	-0.4433	-0.3567	-0.3275	-0.35	-0.255	-0.3667
Surprise	0.00%	0.00%	0.00%	0.00%	+20.00%	+24.44%	-19.12%	-13.64%	-5.00%	-3.13%	-9.46%	-24.44%	-17.19%	+19.70%	-110.34%	+23.30%	-21.61%	-3.82%	+5.71%	-52.94%	+37.28%

LGVN

LGVN fundamentals

LGVN Q4 2025 Earnings

Earnings Call

You can ask Aime

LGVN

LGVN fundamentals

LGVN Q4 2025 Earnings

Earnings Call

LGVN Earnings Call Summary for Q4/20254:30 PM on Mar 17, 2026

LGVN Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

LGVN Earnings Call Summary for Q2/20254:30 PM on Aug 13, 2025

LGVN Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

LGVN Earnings Call Summary for Q4/20244:30 PM on Feb 28, 2025

You can ask Aime